Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Neurology

• Publication date

  2014-06-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00415-014-7384-xPMID 24888315
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progressive supranuclear palsy

  2015cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type

  2013cited by this paper
• Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients.

  2013influential reference
• Multiple system atrophy–parkinsonism with slow progression and prolonged survival: A diagnostic catch

  2012cited by this paper
• Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy

  2011cited by this paper
• The in vivo distribution of brain tissue loss in Richardson’s syndrome and PSP‐parkinsonism: a VBM‐DARTEL study

  2010cited by this paper
• Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.

  2010cited by this paper
• What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy‐parkinsonism (PSP‐P)?

  2010cited by this paper
• Survival in progressive supranuclear palsy and frontotemporal dementia

  2010influential reference
• Assessment of dementia in patients with multiple system atrophy

  2009cited by this paper
• Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges.

  2009cited by this paper
• Survival in multiple system atrophy

  2008cited by this paper
• Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy.

  2008cited by this paper
• Second consensus statement on the diagnosis of multiple system atrophy

  2008cited by this paper
• Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

  2008influential reference
• Different Tau Pathology Pattern in Two Clinical Phenotypes of Progressive Supranuclear Palsy

  2008cited by this paper
• Pure akinesia with gait freezing: A third clinical phenotype of progressive supranuclear palsy

  2007cited by this paper
• Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy.

  2007cited by this paper
• Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.

  2007cited by this paper
• A clinical rating scale for progressive supranuclear palsy.

  2007cited by this paper
• Natural History of Progressive Supranuclear Palsy: A Clinicopathologic Study from a Population of Brain Donors

  2005cited by this paper
• The Frontal Assessment Battery (FAB): normative values in an Italian population sample

  2005cited by this paper
• Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.

  2005cited by this paper
• Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing

  2005cited by this paper
• Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)

  2004cited by this paper
• Natural history and clinical features of progressive supranuclear palsy: a clinical study

  2003cited by this paper
• Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia

  2003cited by this paper
• Clinical features and natural history of progressive supranuclear palsy

  2003cited by this paper
• Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy.

  2002cited by this paper
• The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.

  2002cited by this paper
• Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients.

  2002cited by this paper
• Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders.

  2001cited by this paper
• Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy

  2001cited by this paper
• What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?

  2000cited by this paper
• The FAB: A frontal assessment battery at bedside

  2000cited by this paper
• Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study.

  1999cited by this paper
• The natural history of degenerative ataxia: a retrospective study in 466 patients.

  1998cited by this paper
• Progressive supranuclear palsy

  1998cited by this paper
• Consensus statement on the diagnosis of multiple system atrophy

  1998cited by this paper
• Survival of patients with pathologically proven multiple system atrophy

  1997cited by this paper
• Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)

  1996cited by this paper
• Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.

  1996cited by this paper
• Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)

  1996cited by this paper
• Clinicopathological study of 35 cases of multiple system atrophy.

  1995cited by this paper
• The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal.

  1995cited by this paper
• Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.

  1994cited by this paper
• Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.

  1994cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper
• Prevalence and natural history of progressive supranuclear palsy

  1988cited by this paper
• Unified Parkinson's Disease Rating Scale

  1987cited by this paper
• The clinical features and natural history of the Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy)

  1986cited by this paper
• Recent Developments in Parkinson's Disease

  1986cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• Parkinsonism

  1967cited by this paper

• Cross-sectional and longitudinal validation of short and long versions of the progressive supranuclear palsy quality of life scale.

  2025cites this paper
• The Diagnostic Value of 18F-FDG PET in Parkinson Disease Based on Voxel Analysis.

  2025cites this paper
• A meta-analysis of survival and prognostic factors in multiple system atrophy

  2025cites this paper
• The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis

  2024cites this paper
• Japanese longitudinal biomarker study in progressive supranuclear palsy and corticobasal degeneration: Clinical features of the first registered patients and short-term follow-up analysis

  2024cites this paper
• Clinical milestones as triggers for palliative care intervention in progressive Supranuclear palsy and multiple system atrophy.

  2023cites this paper
• Clinical features of progressive supranuclear palsy

  2023cites this paper
• Differentiating between common PSP phenotypes using structural MRI: a machine learning study

  2023cites this paper
• Progressive supranuclear palsy: current approach and challenges to diagnosis and treatment

  2023cites this paper
• Uncovering spatiotemporal patterns of atrophy in progressive supranuclear palsy using unsupervised machine learning

  2023cites this paper
• The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT)

  2022cites this paper
• Limited access to health care in patients with atypical parkinsonism during COVID-19 era may lead to higher mortality

  2022cites this paper
• When to initiate palliative care in neurology.

  2022cites this paper
• Long‐Duration Progressive Supranuclear Palsy: Clinical Course and Pathological Underpinnings

  2022cites this paper
• Risk of SARS‐CoV‐2 infection, hospitalization, and death for COVID‐19 in people with Parkinson disease or parkinsonism over a 15‐month period: A cohort study

  2022cites this paper
• Clinical Spectrum of Tauopathies

  2022cites this paper
• The Burden of Progressive Supranuclear Palsy on Patients, Caregivers, and Healthcare Systems by PSP Phenotype: A Cross-Sectional Study

  2022cites this paper
• The Application of Deep Brain Stimulation for Progressive Supranuclear Palsy: A Systematic Review

  2022cites this paper
• Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study

  2022cites this paper
• “Parkinson’s disease” on the way to progressive supranuclear palsy: a review on PSP-parkinsonism

  2021cites this paper
• Predictors of survival in frontotemporal lobar degeneration syndromes

  2021cites this paper
• Multiple system atrophy - a clinicopathological update.

  2020cites this paper
• Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P)—A Clinical Challenge at the Boundaries of PSP and Parkinson's Disease (PD)

  2020cites this paper
• A Convenient Prognostic Tool and Staging System for Progressive Supranuclear Palsy

  2020cites this paper
• Risk of Hospitalization and Death for COVID‐19 in People with Parkinson's Disease or Parkinsonism

  2020cites this paper
• Síndrome de Blue Rubber Bled Nevus. Presentación de un caso

  2019cites this paper
• Predictors of survival in progressive supranuclear palsy and multiple system atrophy : a systematic review and meta analysis

  2019cites this paper
• Emerging drugs for progressive supranuclear palsy

  2019cites this paper
• Clinical Milestones Preceding the Diagnosis of Multiple System Atrophy and Progressive Supranuclear Palsy: A Retrospective Cohort Study

  2019cites this paper
• Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability.

  2019cites this paper
• Prognostic importance of apathy in syndromes associated with frontotemporal lobar degeneration

  2019cites this paper
• Midbrain/pons area ratio and clinical features predict the prognosis of progressive Supranuclear palsy

  2019cites this paper
• Natural clinical course of progressive supranuclear palsy in Chinese patients in Hong Kong.

  2019cites this paper
• Progressive Supranuclear Palsy: New Diagnostic and Therapeutic Strategies

  2018cites this paper
• The diagnosis of progressive supranuclear palsy: current opinions and challenges

  2018cites this paper
• Beyond the midbrain atrophy: wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy

  2017cites this paper
• Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy

  2017cites this paper
• Quality of life and palliative care need in multiple system atrophy and progressive supranuclear palsy : a pilot study using quantitative and qualitative methods

  2017cites this paper
• Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy.

  2017cites this paper
• Natural history and predictors of survival in progressive supranuclear palsy.

  2017cites this paper
• Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis

  2017cites this paper
• Clinical Features in a Danish Population-Based Cohort of Probable Multiple System Atrophy Patients

  2016cites this paper
• Presentación de una paciente portadora de parálisis supranuclear progresiva

  2016cites this paper
• Progressive supranuclear palsy: progression and survival

  2016cites this paper
• PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy

  2016cites this paper
• The Diagnosis and Natural History of Multiple System Atrophy, Cerebellar Type

  2016cites this paper
• Impact of Aspiration Pneumonia on the Clinical Course of Progressive Supranuclear Palsy: A Retrospective Cohort Study

  2015cites this paper
• Comparación de la calidad de vida en pacientes con parálisis supranuclear progresiva y enfermedad de Parkinson y su repercusión en el cuidador

  2015cites this paper
• Quality of life in patients with progressive supranuclear palsy: one-year follow-up

  2015cites this paper
• Acétogénines d’Annonaceae et parkinsonismes atypiques : de la biodisponibilité de l’annonacine à l’exposition alimentaire.

  2015cites this paper